Mitral valve prolapse (MVP) is a common valvular heart disease associated with a variety of frightening symptoms. Beta-adrenergic blockers along with calcium channel blockers and anxiolytics are widely used to treat symptoms associated with MVPS despite a lack of evidence that supports their efficacy. This study examined the relationship between prescribed medication use and frequency and intensity of MVPS symptoms. A descriptive cross-sectional survey design was used. Descriptive statistics and Cramèr’s V correlational analysis were used to answer the research questions. Self-completed questionnaires were mailed to 2,282 MVPS individuals older than 21 years of age throughout the United States and Canada previously diagnosed with MVPS. Of the 837 participants, 337 (40%) were taking one or more medications. Although there were significant positive correlations between anxiety and calcium channel blockers, chest pain and digoxin, and mood swings and digoxin, the correlations were very weak.
Benjamin, E. (2001). Mitral valve prolapse: Past misconceptions and future research directions. American Journal of Medicine, 111, 726-728.
2.
Bonow, R., Carabello, B., De Leon, A., Edmunds, H., Freed, B., Gaasch, W., et al. (1998). ACC/AHA guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on management of patients with valvular heart disease). Journal of the American College of Cardiology, 32, 1486-1588.
3.
Boudoulas, J., Kolibash, A., Baker, P. L., King, B., & Wooley, C. (1989). Mitral valve prolapse and the mitral valve prolapse syndrome: A diagnostic classification and pathogenesis of symptoms. American Heart Journal, 118, 796-818.
4.
Boudoulas, H., & Wooley, C. (2000). Mitral valve prolapse: Clinical presentation, diagnostic evaluation, and therapeutic considerations. In H. Boudoulas & C. Wooley (Eds.), Mitral valve prolapse and the mitral valve prolapse syndrome (2nd ed., pp. 305-366). New York: Futura Publishing Co.
5.
Burroughs, V. (2003). The importance of individualizing prescribing among genetically and culturally diverse groups. Group Practice Journal, 52(3), 1-3.
6.
Devereux, R., Jones, E., Roman, M., Howard, B., Fabsitz, R., Liu, J., et al. (2001). Prevalence and correlates of mitral valve prolapse in a population-based sample: The strong heart study. American Journal of Medicine, 111, 679-685.
7.
Freed, L., Levy, D., Levine, R., Larson, M., Evans, J., Fuller, D., et al. (1999). Prevalence and clinical outcome of mitral valve prolapse. New England Journal of Medicine, 341, 1-7.
8.
Jeresaty, R. (1985). Mitral valve prolapse: An update. Journal of the American Medical Association, 254, 793-795.
9.
Pratt, C., Young, J., Wierman, A., Borland, R., Seals, A., Leon, C., et al. (1986). Complex ventricular arrhythmias associated with the mitral valve prolapse syndrome. Effectiveness of moricizine (Ethmozine) in patients resistant to conventional antiarrhythmics. American Journal of Medicine, 80, 626-632.
10.
Saltissi, S., Crowther, A., Byrne, C., Clark, S., Jenkins, B., & Webb-Peploe, M. (1983). The effects of oral digoxin therapy in primary mitral leaflet prolapse. European Heart Journal, 4, 828-837.
11.
Scordo, K. (1990). The effects of aerobic exercise on symptomatic females with mitral valve prolapse syndrome. Unpublished doctoral dissertation, Ohio State University.
12.
Scordo, K. (1991). The effects of aerobic exercise on symptomatic women in mitral valve prolapse. American Journal of Cardiology, 76, 863-868.
13.
Scordo, K. (1996). Taking control: Living with mitral valve prolapse syndrome (2nd ed.). Cincinnati, OH: Kardinal.
14.
Scordo, K. (2000). The treatment of mitral valve prolapse syndrome in a nurse-managed out-patient mitral valve prolapse clinic. Nursing Clinics of North America, 35, 1005-1017.
15.
Scordo, K. (2001). Factors associated with participation in a mitral valve prolapse support group. Heart & Lung: The Journal of Critical Care, 30, 128-137.
16.
Scordo, K. (2005). Mitral valve prolapse syndrome health concerns, symptoms, and treatments. Western Journal of Nursing Research, 27, 390-405.
17.
Scordo, K. (2006). [Mitral valve prolapse syndrome: Health concerns, symptoms and treatment]. Unpublished raw data.
18.
Theal, M., Sleik, K., Anand, S., Yi, Q., Yusuf, S., & Lonn, E. (2004). Prevalence of mitral valve prolapse in ethnic groups. Canadian Journal of Cardiology, 20, 511-515.
19.
Utz, S., & Ramos, M. (1993). Mitral valve prolapse and its effects: A programme of inquiry with Orem’s self-care deficit theory of nursing. Journal of Advanced Nursing, 18, 743-751.
20.
Winkle, R., Lopes, M., Goodman, D., Fitzgerald, J., Schroeder, J., & Harrison, D. (1977). Propranolol for patients with mitral valve prolapse. American Heart Journal, 93, 422-427.
21.
Zwanzger, P., Baghai, T., Schule, C., & Rupprecht, R. (2000). Treatment of mitral valve prolapse and panic disorder with metoprolol. The World Journal of Biological Psychiatry: The Official Journal of the World Federation of Societies of Biological Psychiatry, 1, 124-125.
